Textbook of Erectile Dysfunction

Culley C. Carson, Roger Kirby, Irwin Goldstein, Michael Wyllie

• Publisher: CRC Press
• Year: 2008
• eBook ISBN:
  9781040168752
• Topic: Medicine
• Subtopic: Pharmacology

Erectile dysfunction (ED) affects 20-30 million American men, most of whom are over 50 years of age. In a UK-based study, 32% of British men had difficulty obtaining an erection, 20% with maintaining an erection. In recent years the physiology and pathophysiology of ED  have changed our understanding of what ED is from a purely psychological-b

Table of contents

• Cover Page
• Halftitle Page
• Title Page
• Copyright Page
• Dedication Page
• Contents
• List of Contributors
• Preface
• 1 The history of erectile dysfunction
• 2 The history of the International Society for Sexual Medicine
• 3 Epidemiology of erectile dysfunction
• 4 Anatomy of erectile function
• 5 Microscopic anatomy of erectile function
• 6 Vascular physiology of erectile function
• 7 Central nervous system control of sexual function in males and females
• 8 Ejaculatory physiology
• 9 Endocrinology of male sexual function
• 10 Pathophysiology of erectile dysfunction: molecular basis
• 11 Neurotransmitters in the corpus cavernosum: nitric oxide and beyond
• 12 Receptor pharmacology related to erectile dysfunction
• 14 Erectile dysfunction and treatment of carcinoma of the prostate
• 15 Vascular risk factors and erectile dysfunction
• 16 Mediterranean diet and erectile dysfunction
• 17 Pharmacological risk factors for altered male sexual function
• 18 Male sexual dysfunction and the prostate
• 19 Basic assessment of the patient with erectile dysfunction
• 20 The contemporary role of penile duplex scanning in sexual dysfunction
• 21 Imaging in erectile dysfunction
• 22 Neurophysiologic testing in erectile dysfunction
• 23 Biopsy of the corpus cavernosum
• 24 Endocrine evaluation of male sexual function
• 25 The biopsychosocial evaluation of erectile dysfunction
• 26 Erectile dysfunction: the ouple context
• 27 Primary care evaluation and treatment of erectile dysfunction: American perspective
• 28 Phosphodiesterase type 5 inhibitors: molecular basis for pharmacological effects
• 29 Phosphodiesterase type 5 inhibitors: non-erecti e dysfunction cardiovascular effects
• 30 Sildenafil: first in the therapeutic class of phosphodiesterase type 5 inhibitors
• 31 Tadalafil: Long-acting phosphodiesterase type 5 inhibitor
• 32 Vardenafil: a biochemically potent hosphodiesterase type 5 inhibitor
• 33 The Princeton Guidelines or treatment
• 34 A Phosphodiesterase type 5 inhibitors: safety and adverse events
• 35 Diagnosis and treatment of hypogonadism
• 36  Central nervous system agents for 30 he treatment of erectile dysfunction
• 37 Intracavernosal therapy for erectile dysfunction
• 38 Invicorp in erectile dysfunction
• 39 Vacuum systems for erectile dysfunction
• 40 Integrated sex therapy: a psychosocial-cultural perspective integrating behavioral, cognitive, and medical approaches
• 41 Gene therapy in erectile dysfunction: an update
• 42 Stem and endothelial progenitor cells in erectile biology: future therapeutic applications and potential biomarker for erectile dysfunction
• 43 a Mechanical, malleable, and soft semi-rigid penile implants for erectile dysfunction
• 44 Inflatable penile prostheses in erectile dysfunction (including penile shaft re-modeling in Peyronie' s disease)
• 45 Inflatable penile prostheses
• 46 Design, development, and use of 40 questionnaires and surveys in the evaluation and management of sexual dysfunction: erectile dysfunction
• 47  Assessment of male ejaculatory disorders
• 48 A O Cl'n'cal trial design for aO erectile dysfunction
• 49 Sexual function in congenital anomalies
• 50 Veno-occlusive impotence and  erectile dysfunction: treatment and outcomes
• 51 Penile fracture: evaluation and management
• 52 Risks, complications, and outcomes of penile lengthening and augmentation procedures
• 53 Peyronie's disease: evaluation and review of non-surgical therapy
• 54 Surgical treatment of Peyronie's disease
• 55  Priapism
• 58 Phosphodiesterase type 5 inhibitor therapy for priapism
• 58 Phosphodiesterase type 5 inhibitors or the treatment of women' s sexual dysfunction
• 59 Erectile dysfunction and diabetes
• 60 Chronic renal failure and sexual dysfunction
• 61 Evaluation of ejaculatory disorders
• 62 Medical treatment of ejaculatory dysfunction
• 63 Topical agents for the treatment of premature ejaculation
• 64 Potency-preserving surgery: radical  prostatectomy and other pelvicsurgery
• 65 Rehabilitation of sexual function following prostatectomy
• 66 Sexual dysfunction and prostate  cancer therapy
• 67 Gender reassignment surgery
• Index